# Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

> **NCT04632758** · PHASE3 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 292 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** WX-0593 Tablets
- **DRUG:** crizotinib

## Key facts

- **NCT ID:** NCT04632758
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 292 (ACTUAL)
- **Last updated:** 2023-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04632758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04632758, "Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04632758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*